<DOC>
	<DOC>NCT02231008</DOC>
	<brief_summary>The aim of this study is to investigate tasimelteon vs. placebo on sleep disturbances of individuals with Smith-Magenis Syndrome.</brief_summary>
	<brief_title>Evaluating the Effects of Tasimelteon vs Placebo on Sleep Disturbances in SMS</brief_title>
	<detailed_description />
	<mesh_term>Smith-Magenis Syndrome</mesh_term>
	<criteria>1. A confirmed clinical diagnosis of SMS 2. Informed consent from the patient or the legal guardian 3. Male or female between the ages of 16 65 years of age 4. History of sleep disturbances 5. Willing and able to comply with study requirements and restrictions 1. Unable to dose daily with medication and have an appointed caregiver complete the required outpatient assessments 2. Exposure to any investigational drug, including placebo, within 30 days or 5 halflives (whichever was longer) of screening 3. Any other sound medical reason as determined by the clinical investigator</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>SMS</keyword>
</DOC>